Archer further enhances biochip gFET design for advanced sensing and sends to commercial foundry partner
SYDNEY, Australia, July 30, 2023 (GLOBE NEWSWIRE) -- Archer Materials Limited (“Archer”, the “Company”, “ASX: AXE”), a semiconductor company advancing the quantum computing and medical diagnostics industries, has developed a next generation biochip fabrication to better detect and control disease samples on a single graphene field effect transistor (“gFET”) design. The design has been sent to a commercial foundry partner for a whole four-inch wafer run for validation.
- Archer Materials has advanced its biochip gFET design to improve its detection and control capabilities which link to the goal of single device multiplexing.
- The design has been sent to a commercial foundry partner for a whole four-inch wafer run for validation.
- The gFET design also has functional surfaces and components, for both the sensor and control of the biochip platform.
- Archer expects the advanced gFETs on a single four-inch wafer to be delivered by the additional commercial foundry partner by the end of 2023.